LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather

Archive ouverte

Fontaine, H. | Hezode, C. | Zoulim, F. | Samuel, D. | Bourlière, M. | Haour, G. | Dorival-Mouly, C. | Leroy, V. | de Ledinghen, V. | Lucier, S. | Larrey, D. | Tran, A. | Metivier, S. | Benhamou, Y. | Hubert-Fouchard, I. | Habersetzer, F. | Marcellin, P. | Mathurin, P. | Alric, Laurent | Bronowicki, J. -P. | Guyader, D. | Loustaud-Ratti, V. | Minello, A. | Riachi, G. | Rosa, I. | Simony, M. | Diallo, A. | Carrat, F. | Pol, S

Edité par CCSD -

International audience. Introduction:Real-life results of the Sofosbuvir (SOF)/Simeprevir(SIM) combination have been extensively reported in genotype 1-infected patients but there are few or no data regarding genotype 4-infected patients for the SOF/SIM or the SOF-Daclatasvir (DCV)combinations. In January 2015, more than 3003 patients of theFrench observational cohort ANRS CO22 HEPATHER were given thenew oral antivirals in 32 centers: we report the preliminary resultsof the Sofosbuvir-based combinations with DCV or SIM, with orwithout ribavirin (RBV), in Genotype 4-infected patients.Material and Methods:Demographics, history of liver disease werecollected at entry in the cohort. Clinical, adverse events, andvirological data were collected throughout treatment and post-treatment follow-up.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion